Novel Immunotherapy Treatments: The Adverse Effects of Nivolumab.

Angela Magdaleno DO  
Lehigh Valley Health Network, angela.magdaleno@lvhn.org

Wael Hanna MD  
Lehigh Valley Health Network, Wael_A.Hanna@lvhn.org

Follow this and additional works at: https://scholarlyworks.lvhn.org/medicine
Part of the Internal Medicine Commons, Medical Sciences Commons, and the Nephrology Commons

Published In/Presented At

This Poster is brought to you for free and open access by LVHN Scholarly Works. It has been accepted for inclusion in LVHN Scholarly Works by an authorized administrator. For more information, please contact LibraryServices@lvhn.org.
**INTRODUCTION**

Nivolumab is a checkpoint immunotherapy that has become a primary treatment modality for patients with advanced melanoma and non-small cell lung carcinoma (NSCLC). New immunotherapy treatments can result in unique adverse events due to increased inflammation in any organ in the body.

**DISCUSSION**

Immune-related inflammation and metastatic disease in the pancreas in combination with nivolumab immunotherapy likely caused pancreatic insufficiency resulting in new-onset diabetes. The cause of this phenomenon is presumed to be due to inappropriate activation of T-cells resulting in damage to normal tissues. Few case reports have highlighted adverse effects of nivolumab causing immune-related pancreatitis or rapid onset insulin-dependent diabetes. The case report herein demonstrates both immune-related pancreatitis and new-onset insulin-dependent diabetes developing after only one treatment with nivolumab. All medical professionals should be able to recognize immune-related adverse events due to immunotherapy medications to appropriately diagnose patients.

**CASE REPORT**

A 64-year-old Vietnamese male with a history of stage IIIA NSCLC was treated with Taxol, Carboplatin and radiation therapy with good response. Two years later, computed tomography (CT) scan demonstrated metastases to the liver and pancreas. The patient began treatment with nivolumab. Two weeks after the initial nivolumab treatment, the patient complained of significant abdominal pain. Repeat CT imaging showed disease progression in the liver and pancreas with mild inflammation of the pancreatic tail. Hospital admission blood work showed lipase of 4479 U/L and CRP of 179 mg/L, which is consistent with immune-related pancreatitis. He was treated with methylprednisolone 1.2mg/kg/day with improvement in pain and lipase levels. Ten days after starting steroid treatment, outpatient lab work revealed significant lab derangements including blood glucose 649 mg/dL, sodium 126 mmol/L, elevated creatinine of 1.35 mg/dL and an anion gap of 14. The patient had no known history of diabetes. The patient did complain of polyuria and polydipsia for the previous 10 days. Hemoglobin A1C resulted at 11%. Glutamic acid decarboxylase antibody was negative, islet cell antibody was negative, zinc transporter 8 antibody was negative, and C Peptide level was low at 0.3 ng/mL. The patient was started on insulin as treatment for his elevated blood sugars and low insulin levels.

**Image 1:** T cells inactivated by cancer cells through PD-L1/PD-L2 receptor

**Image 2:** Nivolumab utilized to maintain T cell activation against cancer cells, and some healthy cells

**Image 3:** CT Abdomen/Pelvis. Pancreatic mass noted.

**Image 4:** CT Abdomen/Pelvis. Pancreatic inflammation noted.